Rationale: Metformin has been demonstrated to decrease infarct size (IS) and prevent postinfarction left ventricular (LV) remodeling in rodents when given intravenously at the time of reperfusion. It remains unclear whether similar cardioprotection can be achieved in a large animal model.
D espite considerable investigation for many years, the only therapy demonstrated to reduce myocardial infarct size (IS) that has been translated into clinical application has been immediate reperfusion of the infarct related artery. 1, 2 This is now routinely effected via percutaneous coronary intervention for patients presenting with ST-segment-elevation myocardial infarction (MI). Recent interest has focused on myocardial postconditioning with interventions that can be administered immediately before or after myocardial reperfusion. One putative target has been limiting mitochondrial dysfunction by attenuating the opening of the mitochondrial permeability transition pore during the initial minutes after reperfusion. 3, 4 In this regard, preclinical studies of reperfused MI in mouse and rat models have suggested that metformin may be a widely available and inexpensive candidate that can reduce myocardial IS. 5 Elegant mechanistic studies in mice and rats have demonstrated that these favorable actions reflect metformin's ability to stimulate AMP kinase, phosphorylate eNOS (endothelial nitric oxide synthase), and increase adenosine during ischemia. 6, 7 These beneficial effects are independent of blood sugar lowering or underlying diabetes mellitus and can be demonstrated in normal animals. 8 
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Although each of these biochemical pathways can be pharmacologically manipulated to reduce experimental IS when administered before ischemia, metformin has also been shown to reduce IS when given immediately before reperfusion. 9 In addition to reducing IS, murine models have demonstrated favorable effects on postinfarction remodeling. 10, 11 Although metformin had not been shown to reduce IS in a large animal model, the enthusiasm over observations in rodent models of ischemia led to rapid translation to a randomized clinical trial employing oral metformin after primary percutaneous coronary intervention for STsegment-elevation MI. Unfortunately, when therapy was started 1 to 2 hours after reperfusion, metformin had no effect on left ventricular (LV) function or other outcome variables. 12 This could reflect the failure to administer metformin before reperfusion or the inability to translate the molecular mechanisms and observations in rodents with preclinical large animal studies employing blinding, randomization, and rigorous methodology.
These previous considerations and the potential impact of metformin as an inexpensive adjunctive therapy to reduce IS underscore the need for pivotal testing in a large animal model of ischemia/reperfusion having more fidelity with the pathophysiology of the human heart. We, therefore, determined whether metformin postconditioning could be demonstrated to reduce IS in closed-chest swine. An approach was developed to administer metformin parenterally immediately before reperfusion to achieve high intracoronary plasma levels comparable to preclinical rodent studies. To ensure rigor, we employed blinding, randomization, and imaging methodology that could be implemented in routine clinical care (echocardiography and multidetector computed tomography [MDCT] ).
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
All procedures and protocols conformed to institutional guidelines for the care and use of animals in research and were approved by the University at Buffalo Institutional Animal Care and Use Committee. All personnel involved in data collection and analysis (including hemodynamics, computed tomographic [CT] imaging, echocardiography, and histopathologic measurements) were blinded to the treatment status of each animal. We allocated 10 animals per treatment group based on a prospective power analysis using myocardial IS in swine from the CAESAR study (Consortium for Preclinical Assessment of Cardioprotective Therapies). 13 This provides 85% power to detect a 36% reduction in IS as a percentage of the ischemic area-at-risk (AAR) with a 2-sided 5% type I error rate.
Experimental Design
Swine were studied in the closed-chest state using a protocol summarized in Figure 1 . Yorkshire-cross bred pigs, 3 to 4 months of age, were purchased from WBB Farm (Alden, NY). After initial sedation with a Telazol (100 mg/mL)/Xylazine (100 mg/mL) mixture (0.04 mL/kg intramuscular), anesthesia was maintained with a continuous infusion of propofol (5-10 mg/kg per hour) through an 18G angiocath placed in an ear vein. All animals received prophylactic antibiotics (cefazolin; 1000 mg, intravenous). They were subsequently intubated and mechanically ventilated with oxygen at a respiratory rate of 15 to 20 breaths/min throughout the study. ECG leads, pulse oximetry, and temperature were monitored throughout the study. A 6F introducer was placed in the femoral vein, and a 7F introducer was placed in the femoral artery. A baseline blood sample was drawn from the femoral vein (≈20 mL) and aliquoted into 12 tubes (6 serum, 3 EDTA, 3 EDTA+protease inhibitor). Arterial blood gases were assessed throughout the study and maintained within physiological levels via adjustments in ventilation rate and volume. After heparinization (3000 units, intravenous), baseline heart rate Nonstandard Abbreviations and Acronyms 
Novelty and Significance
What Is Known?
• Metformin is a commonly used, well-tolerated, and inexpensive antidiabetic drug that has been shown to exert cardioprotective effects when tested in small animal models of myocardial ischemia/reperfusion injury.
• Although a clinical study testing the efficacy of oral metformin initiated 1 to 2 hours after reperfused myocardial infarction was negative, this may have resulted from the failure to administer metformin before reperfusion.
What New Information Does This Article Contribute?
• In a blinded and randomized preclinical study, intravascular administration of metformin immediately before reperfusion failed to provide cardioprotection in a porcine model of acute myocardial infarction.
• Despite achieving high circulating concentrations quickly and without adverse side effects, metformin treatment failed to reduce infarct size or improve left ventricular function 1 week after reperfusion.
• These findings argue against further clinical testing of acute metformin administration at the time of reperfusion to reduce infarct size in humans and highlight the importance of conducting rigorous preclinical large animal studies of putative cardioprotective therapies before clinical translation.
Despite several decades of research, a pharmacological therapy capable of limiting reperfusion injury and reducing infarct size when administered alongside percutaneous coronary intervention in patients experiencing acute myocardial infarction has yet to be identified. Metformin, a widely available antidiabetic drug, has exhibited cardioprotective effects in rodent models of myocardial ischemia/reperfusion injury but has not been tested in a clinically relevant large animal model. Here, we developed an approach to administer metformin intravascularly immediately before reperfusion to achieve high intracoronary plasma levels in a porcine model of myocardial infarction. In a blinded, randomized, and vehicle-controlled preclinical study, metformin did not reduce infarct size nor improve left ventricular function 1 week after reperfusion. Thus, acute administration of metformin as a cardioprotective therapy at the time of reperfusion does not appear to be a viable candidate for future clinical testing. Furthermore, these results support continued caution in translating results of preclinical studies in small animals to humans without confirming efficacy in rigorous large animal studies using methodology that is similar to that used in clinical trials. September 28, 2018
and femoral arterial blood pressure were assessed. Baseline LV function was also assessed via transthoracic 2-dimensional echocardiography (GE Vivid 7) using a right parasternal approach with the pig in the left lateral recumbent position. Measurements of ejection fraction and regional wall thickening were obtained using American Society of Echocardiography criteria. After data collection, amiodarone (5 mg/kg bolus) and lidocaine (1.5 mg/kg bolus) were administered intravenously to minimize the risk of arrhythmias. Defibrillator pads were placed on the animal's chest and connected to a LIFEPAK 15 defibrillator (Physio-Control). If ventricular fibrillation developed during the study, biphasic defibrillation starting at 200 to 250 Joules was attempted. If unsuccessful, increases of 50 to 60 Joules were attempted until the maximum of 360 Joules was reached. If successful, pressure was closely monitored to ensure appropriate recovery. If prolonged refractory ventricular fibrillation developed, the pig was excluded from the study.
After an additional bolus of heparin (5000 U intravenous), a 6F guiding catheter (Cordis, Hockey Stick) was advanced into the left main coronary artery for angiography (Iohexol, 350 mgI/mL). We administered nitroglycerin (250 μg intracoronary) and inserted a guidewire into the left anterior descending coronary artery (LAD) artery. Subsequently, an appropriately sized balloon angioplasty catheter (Boston Scientific, Maverick, 2.5-3.25 mm×6-12 mm long) was advanced into the LAD and positioned just distal to the second diagonal artery targeting an ischemic AAR of ≈20% of LV mass. The angioplasty balloon was transiently inflated to 6 to 9 atm (<20 seconds) to angiographically confirm that the diameter was appropriate to completely occlude the LAD. The animals were subsequently transported the adjacent CT scanner (GE Discovery VCT PET/CT) to begin the infarct protocol. We inflated the balloon catheter to totally occlude the LAD for 60 minutes and assessed the ischemic AAR at the onset of ischemia via contrast-enhanced MDCT as outlined below. Amiodarone (0.04 mg/kg per minute infusion) and lidocaine (and 0.05 mg/kg per minute infusion) were administered intravenously beginning 10 minutes before the onset of ischemia and continued throughout the occlusion period and the first 15 minutes of reperfusion. After assessing the AAR with MDCT and with the balloon occlusion maintained, pigs returned to the adjacent physiology laboratory where we repeated coronary angiography to document that the LAD remained occluded. At 30 minutes, an additional heparin bolus (4000 U) was administered to ensure continued anticoagulation.
Eight minutes before reperfusion, animals were randomly allocated to receive a bolus of metformin (5 mg/kg intravenously in 20 mL of saline; Sigma #PHR1084) or saline with all study personnel blinded to treatment allocation. Plasma samples to assess metformin concentration were drawn and analyzed as described below. After confirming total LAD occlusion angiographically, an intracoronary infusion of metformin (1 mg/mL per minute, intracorporeal) or saline was started through the guiding catheter. Two minutes after starting the infusion, the balloon was deflated to achieve reperfusion. The metformin infusion continued for 15 minutes of reperfusion at which point metformin, amiodarone, and lidocaine infusions were stopped. The angioplasty balloon and guiding catheter were withdrawn. After 1 hour of reperfusion, a blood sample was collected and angiography repeated to ensure reperfusion in all visible branches. An echocardiogram was performed to assess LV function after which animals were weaned off anesthesia, extubated, and returned to the animal facility for recovery.
Seven days after reperfusion, each animal returned to the laboratory for a terminal physiological study. After sedation and anesthesia as detailed for the initial study, catheters were placed to assess hemodynamics including LV pressure (Millar), and coronary angiography was performed to confirm patency of the LAD. We repeated assessment of LV function with both echocardiography and MDCT (details below). We then advanced a balloon catheter to the site of the initial occlusion, reoccluded the LAD via balloon inflation, and assessed the AAR pathologically by infusing 100 mL of phthalocyanine blue dye (5% w/v in saline) into the LV lumen. Immediately after administration of phthalocyanine blue, the heart was arrested using alternating current fibrillation through a right ventricular trans-venous pacing lead and removed for postmortem analyses.
Pathological Determination of AAR and IS
The heart was immediately excised to determine the pathological AAR and myocardial IS. All investigators and technicians were blinded to treatment allocation. The atria and right ventricle were removed to weigh the LV, which was subsequently sectioned into 8-mm thick concentric rings. Rings were weighed, placed in petri dishes with saline, and imaged with a digital scanner (HP Scanjet G4050) to allow planimetric quantification of the AAR via delineation of the LV area not stained by phthalocyanine blue. Tissue slices were placed in 1% triphenyl tetrazolium chloride (TTC) to stain viable myocardium and again digitized. Pathological AAR and IS were quantified by planimetry using ImageJ software (National Institutes of Health). The infarct and AAR values were averaged between the apical and basal sides of each ring and the volume of infarcted tissue extrapolated using ring weight.
Multidetector Computed Tomography
Contrast-enhanced MDCT was performed with a 0.5 mm×64-slice MDCT scanner (Discovery VCT, GE Healthcare). We assessed the AAR 5 minutes after the onset of LAD occlusion and assessed LV function and IS 7 days after reperfusion. After a scout scan and timing bolus with intravenous iohexol (350 mgI/mL; 10 mL, 4 mL/s), LV function was assessed via arterial phase ECG-gated CT after an intravenous bolus of iohexol (350 mgI/mL; 1 mL/kg at 4 mL/s). Firstpass CT acquisitions were reconstructed in 10% phases from 5% to 95% throughout the entire R-R interval and reformatted at a 6-mm slice thickness in the short axis. Using Vitrea CT Functional Analysis software (Vital Images, Inc), the endocardium and epicardium of each slice were manually traced at end-diastole and end-systole for calculation of LV ejection fraction, LV end-diastolic volume, LV endsystolic volume, LV stroke volume, and LV mass. In addition to LV function, IS was assessed 7 days post-MI using delayed-contrast CT images acquired 5 minutes after contrast administration. Images were reconstructed at end-diastole (95% of the R-R interval) and reformatted to contiguous, 8-mm thick short-axis slices for manual measurement of IS by 2 independent blinded investigators using ImageJ Figure 1 . Experimental protocol. All study personnel were blinded to treatment allocation until completion of data collection and analysis. After baseline data collection including echocardiography and multidetector computed tomography (MDCT) imaging, swine were subjected to a 60-min occlusion of the left anterior descending (LAD) coronary artery in the closed-chest state. Contrast-enhanced MDCT was performed 5 min after the onset of LAD occlusion for assessment of the ischemic area-at-risk (AAR). Eight minutes before reperfusion, a bolus of metformin (5 mg/kg) or saline (vehicle) was administered via intravenous infusion in blinded fashion. Two minutes before reperfusion, an intracoronary infusion of metformin (1 mg/mL per minute) or saline was initiated through the guide catheter engaged in the LAD and maintained until 15 min after reperfusion. Serial echocardiography was performed to assess left ventricular (LV) function, and MDCT imaging was repeated 1 wk post-reperfusion to assess infarct size and LV ejection fraction. Immediately before euthanasia, the LAD was reoccluded, phthalocyanine blue was administered, and the heart was excised for postmortem assessment of the ischemic AAR and infarct size. Please see text for additional details. TTC indicates triphenyl tetrazolium chloride.
software. Infarct size was quantified as absolute infarct volume (g) and also expressed as a percentage of LV mass (%).
To assess the AAR at the time of occlusion, an arterial phase ECG-gated CT was performed 5 minutes after LAD occlusion after an intravenous bolus of iohexol (350 mgI/mL; 2 mL/kg at 4 mL/s). First-pass image acquisitions were reconstructed at mid-diastole (75% of the R-R interval) and reformatted at 8-mm slice thickness in the short axis. The CT AAR was manually traced by 2 independent blinded investigators using ImageJ software and expressed as a percentage of LV mass.
Plasma Metformin Levels
Serial plasma samples were obtained to assess metformin levels. All animals (n=20) were sampled immediately before reperfusion, as well as 1 hour after reperfusion. Additional time points were evaluated 1 minute after the intravenous bolus and 5, 15, and 30 minutes after reperfusion in 8 animals (4 that received metformin). Blood was drawn into a sterile 20 mL syringe and immediately aliquoted into EDTA tubes which were then mixed and placed on ice before centrifugation at 1500g for 15 minutes. The plasma was then collected, aliquoted into cryovials, and stored at −80°C before analysis. We assessed plasma metformin concentration using high pressure liquid chromatography-mass spectroscopy. Because of blinding, all saline animals were also analyzed but showed no detectable levels of metformin. To assess the potential concentration of metformin in red blood cells, red blood cell metformin levels were also measured in 4 animals at the time of reperfusion. We withdrew 1 mL of the red blood cell fraction from the spun-down EDTA tubes, lysed the cells with tween and vigorous vortexing, and analyzed metformin concentrations in a fashion similar to red cell-free plasma samples.
High pressure liquid chromatography was performed on an XBridge Amide 3.5u 2.1×100 mm column (Waters cat no. 186004860). A deuterated-metformin internal standard was used (Toronto Research Chemicals Metformin-d6 cat no. M258812). Analysis was performed on a system equipped with an Agilent Technologies (Palo Alto, CA) model 1100 autosampler, a dual pump, and an Applied Biosystems MDS/Sciex (Foster City, CA) API 3000 mass spectrometer using a turbo-ion spray source. The system control and data analysis were executed using the Analyst software (Applied Biosystems, version 1.4). Chromatography was performed on a C8 Hydrobond AQ column (particle size, 3 m, 2.1 150 mm; MAC-MOD Analytical, Inc, Chadds Ford, PA) equipped with a ColumnSaver precolumn filter (MAC-MOD Analytical, Inc). The mobile phase flow rate was 0.2 mL/min with eluent A consisting of 10 mmol/L ammonium formate and 0.1% formic acid and eluent B consisting of acetonitrile. The mobile phase flow design was as follows: 0 to 4.5 minutes, 40% A/60% B; 4.6 to 6.0 minutes, 10% A/90% B to allow system cleanup; followed by a 4-minute equilibration step at 40% A/60% B. The mass spectrometer was operated in the positive ionization mode. The optimal ion pairs, declustering potential, collision energy, collision exit potential, focusing potential, and excitation potential for betamethasone and prednisolone were found to be 393.3/373.3, 35 V, 15 V, 23 V, 300 V, and 10 V, and 361.3/343.5, 25 V, 15 V, 20 V, 300 V, and 10 V, respectively. High purity nitrogen was used as the curtain and collision gas. The source temperature was set at 350°C.
Inter-and intra-assay precision and accuracy were determined by analyzing 3 replicates at 3 different quality control levels on 3 different days. The criteria for acceptability of the data included accuracy within ±15% SD from the nominal values and a precision of within ±15% relative SD, except for lower limit of quantification, where it did not exceed ±20% of SD.
Assessment of Serum cTnI
Blood samples collected from a peripheral vein at baseline and 1 hour post-reperfusion were allowed to clot at room temperature for 40 minutes, centrifuged at 1500g for 15 minutes, aliquoted, and frozen for storage at −80°C. Serum was thawed once and cardiac troponin I (cTnI) quantified in duplicate with a porcine-specific cTnI ELISA kit for serum (Life Diagnostics, CTNI-9-HS) according to manufacturer's instructions.
Statistical Analysis
Data are expressed as mean±SEM. Differences between treatment groups in serial echocardiographic measurements were assessed by a 2-way mixed ANOVA with repeated measures to account for treatment effect (metformin versus vehicle) and time point (baseline versus 1 hour post-MI and 1 week post-MI). When significant differences were detected, a post hoc Student t test was used for all pairwise comparisons (SPSS Statistics, version 22; IBM). Post hoc tests were not adjusted for multiple comparisons. All other betweengroup differences were assessed using an unpaired Student t test. The Shapiro-Wilk test was used to determine whether data were normally distributed. Serum cTnI values were not normally distributed, thus logarithmic transformations were performed before statistical analysis. For all comparisons, P<0.05 was considered significant.
Results
A total of 30 animals were studied. Three animals were excluded before assignment of treatment. One had anomalous coronary anatomy (antero-septal wall supplied by a large branch of the right coronary artery), a second had refractory ventricular fibrillation during coronary occlusion, and a third had deflation of the angioplasty balloon with partial reperfusion before the 60-minute time point. Of the animals randomized to treatment, 5 were excluded because of sudden death (4 within 24 hours [3 vehicle/1 metformin] and 1 at 3 days post-MI [vehicle]). Two of the vehicle-treated animals that died after randomization to treatment experienced lethal ventricular arrhythmias within the first 15 minutes of reperfusion. This precluded TTC assessment of IS because of insufficient washout time. Of the remaining animals lost to sudden death, TTC IS was assessed in 1 vehicle-treated animal that died 3 days after reperfusion (12.8% of LV mass) and 1 metformin-treated animal that died 1 day after reperfusion (19.4% of LV mass). Two additional animals were excluded because of persistent LAD occlusion after the angioplasty balloon was removed (1 vehicle/1 metformin). Twenty animals completed the protocol (n=10 animals per group).
Metformin Plasma Kinetics
We assessed plasma metformin to document that levels were significantly elevated at the onset of reperfusion (Figure 2) . Figure 2 . Plasma metformin concentrations. Serial plasma samples were obtained to assess metformin levels via high pressure liquid chromatography-mass spectroscopy (n=4). The total dose of metformin administered (including the intravenous bolus and 15-min intracoronary infusion) was 691.1±30.9 mg. The venous concentration at the onset of reperfusion averaged 187±22 µmol/L and rose to reach a peak of 374±35 µmol/L 15 min after reperfusion. Plasma metformin remained elevated after the infusion was stopped, with an average level of 140±13 µmol/L at 1 h after reperfusion. Metformin levels were undetectable in all blood samples collected from saline-treated animals.
The total dose of metformin administered (including the intravenous bolus and 15-minute intracoronary infusion) was 691.1±30.9 mg. The venous concentration at the onset of reperfusion averaged 187±22 µmol/L and rose to a peak value of 374±35 µmol/L 15 minutes after reperfusion. Despite stopping the metformin infusion at this time, plasma concentrations remained elevated for at least 1 hour post-reperfusion when an average level of 140±13 µmol/L was detected. Metformin was undetectable in all blood samples taken from vehicle-treated animals. Red blood cell metformin levels averaged approximately one-third of plasma concentrations throughout the first 30 minutes of reperfusion, with values of 66±19 µmol/L 5 minutes after reperfusion rising to a peak of 127±28 µmol/L 10 minutes later, indicating rapid cellular uptake without concentration over the time frame in which measurements were made. Table 1 summarizes key characteristics of animals receiving metformin versus vehicle-treated controls. Sex, weight, and hemodynamic parameters did not differ between treatment groups. The rectal temperature at the time of reperfusion was similar (37.2°C±0.3°C versus 36.8°C±0.4°C; P=0.47). There was no difference in the number of animals that developed ventricular fibrillation and were successfully defibrillated (2 vehicle/3 metformin). They required 3.5±1.5 and 5.0±2.5 shocks, respectively.
Animal Characteristics

Ischemic AAR
We assessed the ischemic AAR using contrast-enhanced MDCT during occlusion and postmortem phthalocyanine blue dye staining during reocclusion of the LAD 7 days after reperfusion. There were no differences in the AAR in either treatment group when assessed by MDCT or pathology (Figure 3) Figure 4 ). Delayed-contrast MDCT assessment of IS produced similar findings as both groups exhibited a similar IS relative to LV mass (vehicle: 14.2%±1.0% versus metformin: 11.9%±2.1%; P=0.33) 7 days after reperfusion. Although MDCT tended to overestimate IS relative to pathology-derived measurement at this time point, a significant effect of metformin was not observed regardless of measurement technique. Group similarities in IS were corroborated by serum cTnI levels 1 hour after reperfusion, which were similar in vehicle-treated (56.7±13.1 ng/mL) and metformin-treated animals (49.7±18.8 ng/mL; P=0.77) and strongly correlated with TTC IS 1 week later (r=0.84; P<0.01; Figure 5 ). There was no effect of metformin on IS in male or female animals.
Effect of Metformin on Myocardial IS
Effect of Metformin on LV Function
There were no differences in echocardiographic indices of baseline LAD regional function, fractional shortening, or LV ejection fraction between treatment groups (Table 3) . After MI, a significant reduction in LAD regional wall thickening was observed 1 hour (vehicle: 3%±2% versus metformin: 4%±1%; P=0.63) and 1 week (vehicle: 9%±4% versus metformin: 17%±5%; P=0.27) after reperfusion that was similar between treatment groups. Similarities in regional contractile function were paralleled by similar M-mode echocardiography-derived LV ejection fraction values between groups 1 hour (vehicle: 47%±3% versus metformin: 50%±5%; P=0.69) and 1 week (vehicle: 53%±3% versus metformin: 56%±3%; P=0.58) after reperfusion. These echocardiographic measures were supported by MDCT assessment of LV ejection fraction, which was similar between groups 1 week after reperfusion (vehicle: 56%±3% versus metformin: 56%±2%; P=0.98; Table 2 ). 
Discussion
In this blinded, randomized preclinical study, we administered metformin intravascularly immediately before reperfusion followed by an intracoronary infusion during the first 15 minutes of reperfusion to maintain high coronary arterial concentrations of metformin. Despite this, we were unable to demonstrate a significant effect of metformin on our primary end points of myocardial IS normalized to AAR or LV ejection fraction 1 week after reperfusion. These negative results in a clinically relevant closed-chest swine model of ischemia/ reperfusion injury do not support the findings of preclinical studies of metformin demonstrating cardioprotection when administered at the time of reperfusion in open-chest rodent preparations. Nevertheless, the findings are consonant with the inability to translate the preclinical findings in clinical trials evaluating metformin as cardioprotective agent in humans.
Beneficial Effects of Metformin on Cardiovascular Outcomes
Previous studies of experimental myocardial ischemia have demonstrated that metformin administered chronically, immediately before ischemia, or at the time reperfusion can reduce myocardial IS assessed within 24 hours after reperfusion. One study has confirmed reductions in chronic IS several weeks later along with variable improvements in LV function. 11 The preclinical use of metformin in models of ischemic heart disease has been summarized in a recent meta-analysis combining studies employing ex vivo isolated buffer-perfused hearts, as well as blood-perfused hearts.
14 Of note, none of the beneficial effects on IS were studied in a large animal model of infarction although one study found favorable effects on apoptosis in chronic ischemia. 15 As pointed out in this metaanalysis, there was a paucity of methodological detail along Figure 3 . Quantification of the ischemic area-at-risk (AAR). The ischemic AAR was quantified by contrast-enhanced multidetector computed tomography (MDCT) imaging during the primary index occlusion (A), as well as pathologically via coronary reocclusion and injection of phthalocyanine blue 1 wk after reperfusion immediately before euthanasia (B). Both methodologies demonstrated that the ischemic AAR was similar between vehicle-and metformin-treated animals (C). Solid black circles indicate data points for individual animals from each treatment group. LV indicates left ventricle.
with methodological pitfalls among many of the studies. The most noteworthy of these included a lack of blinding of all outcomes and randomization to treatment allocation. This is not unlike most other studies conducted in preclinical models of experimental myocardial ischemia 16 but raise inherent concerns about the rigor and reproducibility of the findings. 13 Key prior studies evaluating metformin administered after the onset of ischemia as well as other potential reasons for our divergent results will be discussed below.
Five prior studies evaluated the effects of metformin administered at the onset of reperfusion on IS in models of regional ischemia/reperfusion injury. Calvert et al 6 demonstrated that intraventricular metformin administered immediately before reperfusion in open-chest mice reduced IS after a 30-minute left coronary occlusion from 51% to 18% of the AAR when assessed 24 hours after reperfusion and improved LV ejection fraction assessed at 7 days. In a subsequent murine study from the same group, Gundewar et al 11 demonstrated that intracardiac metformin reduced IS when administered at the time of reperfusion after a 60-minute occlusion. Interestingly, although a single bolus administered at reperfusion could reduce chronic IS (assessed 1-month postreperfusion), chronic metformin administration was necessary to improve ejection fraction and prevent postinfarction LV remodeling. In contrast, there was no effect of chronic metformin on IS or LV remodeling in a permanent coronary occlusion model, suggesting that reperfusion was necessary for metformin-mediated cardioprotection. 11 The favorable effects of metformin in reperfused infarcts have been shown to be dependent on activating AMP kinase and eNOS and were abolished in AMPkα2 dn and eNOS knockout mice. Parallel studies by Paiva et al 7 using 35 minutes of regional ischemia in buffer-and blood-perfused hearts demonstrated that metformin (50 micromolar ex vivo) administered at reperfusion reduced IS from 42% to 19% and 62% and 34% of AAR, respectively. The beneficial actions were felt to be related to increased myocyte release of adenosine and were blocked with the adenosine antagonist 8-sulfophenyltheophyline. Another ex vivo study by Bhamra et al 9 similarly used 35 minutes of regional ischemia followed by 120 minutes of reperfusion (during the first 15 minutes of which metformin was included in the buffer) and demonstrated a minimum effective dose of metformin (50 μmol/L) necessary to reduce IS from 62% to 35% of the AAR. 9 This effect was believed to be driven by Akt as the cardioprotective effect was abolished by an Akt inhibitor. Interestingly, these authors demonstrated that metformin did not phosphorylate AMP kinase when administered in this fashion. In contrast, a subsequent study stimulated AMP kinase pharmacologically with metformin, as well as the adenosine analog 5-amino-4-imidazolecarboxamide-riboside at the time of reperfusion and reduced IS assessed 2 hours after reperfusion. 17 These favorable actions were attenuated by coadministration of the AMP kinase inhibitor compound C. Collectively, prior preclinical studies identify multiple biochemical pathways that individually can promote or prevent myocardial protection when activated at the time of reperfusion in rodents.
Our findings contrast with prior results in rodents in demonstrating no effect of intracoronary metformin on IS or LV function in swine with reperfused MI. In an effort to avoid potentially confounding effects of postreperfusion edema on the AAR and myocardial salvage, 18 we assessed the AAR with contrast-enhanced MDCT at the time of ischemia, as well as 7 days after MI with conventional postmortem pathology. The similarity in AAR measurements (as a percentage of LV mass) with each modality suggests that this end point was not impacted by the substantial edema that might variably impact IS assessment during the first several days of reperfusion as increasingly demonstrated with serial imaging studies. 19, 20 Neither IS as a function of AAR nor IS as a percentage of LV mass was impacted by metformin treatment. It is plausible that the beneficial effects of metformin observed in previous rodent studies could reflect early assessment of IS within the first 24 hours after reperfusion where there are dynamic changes in AAR from edema. Arguing against this possibility is the fact that Gundewar et al 11 demonstrated that a single bolus of low-dose metformin at reperfusion reduced IS from 14% of LV mass to 9% of LV mass when evaluated 4 weeks after MI.
To ensure that we achieved plasma metformin concentrations that were comparable to previous studies in rats, metformin was administered intravascularly using a systemic loading dose followed by an intracoronary infusion. The systemic levels of metformin achieved during the first 15 minutes of reperfusion varied between 186 and 374 µmol/L and are higher than values previously demonstrated to result in cardioprotection in isolated Langendorff hearts. 9 Furthermore, because we followed the systemic intravenous bolus of metformin with an intracoronary infusion through the LAD guiding catheter for 15 minutes after reperfusion, coronary arterial levels undoubtedly exceeded this. Thus, although we did not directly assess signaling mechanisms potentially altered by metformin, an insufficient metformin concentration is unlikely to explain the lack of a cardioprotective effect. In addition, administering higher metformin doses would not be feasible because the ≈700 mg total dose we administered intravascularly approaches the 1200 mg dose limit beyond which the appearance of lactic acidosis has been reported in other dosing protocols in swine. 21 Finally, although it is difficult to ascertain the role that investigator blinding and rigor have in explaining the differences with prior rodent studies, the inability to reproduce other postconditioning interventions using blinded randomized studies has been demonstrated in the CAESAR study. 13 These investigators demonstrated that cardioprotective interventions such as sodium nitrite and sildenafil administered at the time of reperfusion failed to reduce IS when assessed with blinded and randomized methodology similar to a clinical trial. 22, 23 Despite previous support for the cardioprotective potential of metformin in rodent studies, our study failed to reproduce these findings in a clinically relevant translational swine model, providing further support for the importance of conducting rigorous blinded preclinical large animal studies before advancing putative novel therapeutics to clinical testing.
Methodological Limitations
There are several experimental considerations that merit attention when interpreting the results of this study. First, the goal of this study was to determine the effect of acute metformin administered only at the time of reperfusion in the absence of diabetes mellitus. We cannot exclude the possibility that chronic oral metformin therapy administered to patients for the treatment of diabetes mellitus could chronically precondition the heart when present before the development of ischemia. Pretreatment could reduce IS and, as some have suggested, explain metformin's beneficial effects on cardiovascular outcomes versus insulin and other oral agents used for the treatment of diabetes mellitus. 8 Second, although we powered our study based on the relative reduction in IS seen in prior rodent studies, we were underpowered to identify a smaller treatment effect of metformin. To demonstrate that the small difference in IS that we observed (≈14% difference in IS relative to AAR) was significant would require a sample size of >200 swine. Even with this, the impact of such a small change would be of questionable clinical significance. Third, unlike rodents, swine cannot tolerate a more proximal LAD occlusion without developing a high rate of refractory ventricular fibrillation, which was circumvented by limiting our risk area to ≈20% of the LV. Although this is not unlike humans with reperfused ST-segment-elevation MI, the resultant preservation of ejection fraction may have limited our ability to discern an effect of metformin on cardiac function. Likewise, a longer period of postinfarction remodeling may have revealed apparent differences between treatment groups that were not apparent 1 week after MI. Fourth, in contrast to several previous studies evaluating the cardioprotective potential of metformin, our study included both male and female animals. Although we did not observe a significant difference between male versus female swine, we were not sufficiently powered to detect such a difference if it were to exist, and future studies are necessary to determine if sex influences the efficacy of metformin in reducing IS. Fifth, although the 2 treatment groups were well matched for body temperature during ischemia and reperfusion, the average body temperature of all animals averaged ≈37°C. This was similar to previous studies 24 but slightly lower than the normal value for conscious swine (≈38°C-39°C). This may have contributed to a slight reduction in IS in our experiments relative to other studies conducted at higher body temperatures. 13 Finally, although the extent of collateral blood flow is an important consideration when interpreting results of cardioprotection studies in other species, this issue is largely avoided in pigs because they exhibit minimal native collateral blood flow. Thus, we did not measure myocardial perfusion to assess the extent of collateral blood flow during ischemia. Nevertheless, the effect of collateral flow on the efficacy of metformin may be relevant if tested in other large animal models or humans with more prominent collateral perfusion during ischemia.
Conclusions
In conclusion, metformin failed to produce cardioprotective benefits when begun immediately before reperfusion in closed-chest swine. Despite achieving high circulating concentrations quickly and without adverse effects, metformin was ineffective at reducing IS or producing functional benefits after 1 week. Thus, the acute administration of metformin as a cardioprotective agent at the time of reperfusion is Figure 5 . Serum cardiac troponin I (cTnI) concentrations after myocardial infarction. Circulating serum concentrations of cTnI were quantified by a porcine-specific ELISA assay on venous blood collected at baseline and 1 h after reperfusion. Serum cTnI values rose ≈2000-fold 1 h after reperfusion but were not different between vehicle-and metformin-treated animals (A). A strong correlation was observed between serum cTnI 1 h post-reperfusion and myocardial infarct size assessed by triphenyl tetrazolium chloride (TTC) staining 1 wk later (r=0.84; P<0.01; B). Solid black circles indicate data points for individual animals from each treatment group. probably not a viable candidate for clinical translation to reduce IS in humans. Nevertheless, it may be reasonable to consider whether chronic pretreatment with metformin may be efficacious in future studies considering its safety profile and low cost. Finally, the failure to reproduce experimental results from rodent models underscores continued caution in translating results of preclinical studies in small animals to humans without confirming efficacy in pivotal large animal models of ischemic heart disease using randomization, blinding, and rigorous methodology similar to that used in clinical cardiovascular trials. Although the burden and expense associated with pursuing rigorous preclinical studies are significant, their value is realized by providing important confirmation of rodent studies to avoid expensive futile clinical trials in patients.
